STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

The combination of STALICLA and Firefly Neurosciences’s machine learning platforms and know-how will further strengthen the development of precision medicine for these patients

Geneva, Switzerland27 March 2023, STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). This follows the successful completion of STALICLA’s Phase 1b clinical trial for its lead asset STP1 where EEG measurement was shown to be a powerful predictor of efficacy.

STALICLA and Firefly Neuroscience will leverage their technological platforms including the Databased Endophenotyping Patient Identification (DEPI) platform and the FDA-cleared Brain Network Analytics (BNA™) platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials, sponsored by STALICLA.

Applying BNA™ to the DEPI-driven biologically enriched subgroups of patients with ASD is expected to establish and expand EEG as a biomarker in the field of ASD. EEG measurements will reinforce the DEPI stratification capacity and prediction of treatment response in patients with a behavioral diagnosis of ASD.

STP1 is a tailored treatment candidate for ASD-Phenotype 1, the first DEPI-enriched subgroup of patients. STP1 positive target engagement was demonstrated by specific EEG signal modulation in brain areas of interest.

Lynn Durham, STALICLA’s CEO & Founder, commented: “STALICLA is thrilled to partner with Firefly Neuroscience to advance an EEG-based treatment response marker in the NDD population. STALICLA will leverage its DEPI platform and Firefly Neuroscience’s technology to reinforce its leadership in precision medicine for neurodevelopmental disorders with rapid implementation of precision EEG in our upcoming two phase 2 programs in Autism Spectrum Disorder.”

Jon Olsen, Firefly Neuroscience’s CEO, commented: “Firefly Neuroscience is excited to partner with STALICLA on the advancement of treatment for people with ASD. Using BNA™ to target sub-groups of patients for precision medicine treatment in the CNS space is a core focus for the company. The fact that BNA™ is FDA cleared and used by clinicians in the United States to support therapy decisions for people with mental disorders puts us in a very strong position to build a referral network in support of the commercialization of novel drugs and therapies for the treatment of NDD diseases.”

STALICLA has developed and validated a machine learning platform, DEPI, allowing ASD subgroup identification and precision medicine treatment candidate selection. With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with ASD and their tailored treatments STP1 and STP2. Both STP1 and STP2 are planned to enter Phase 2 clinical trials in 2023.

Firefly Neuroscience’s BNA™ platform is a patented technology that provides an objective, quantified assessment of cognition (brain function). It measures brain function and compares it to an FDA-cleared, normative, age-matched database using proprietary AI and advanced signal processing technology. Firefly Neuroscience’s AI platform (‘Fly-AI’) will help develop future biomarkers and companion diagnostics allowing for the expansion of existing pharma collaborations and partnerships to make the development of new CNS drugs more efficient.

About STALICLA
STALICLA is a precision molecular neuroscience clinical stage biotech company, advancing the first precision medicine platform (DEPI) for patients with neurodevelopmental disorders (NDDs), and neuropsychiatric disorders.
STALICLA’s unique approach is addressing the poor construct validity of behaviourally defined disorders through its unique platform integrating molecular data with human genetic information to create testable clinical hypotheses in psychiatry and neuroscience.
With multiple clinical proof of concepts, DEPI has allowed for the identification of two distinct subgroups of patients with Autism Spectrum Disorder (ASD) and their tailored treatments STP1 and STP2, both of which are planned to enter Phase 2 clinical trials in 2023. STP1 and STP2 hold a multi-billion market potential.
The DEPI platform has been validated in a clinical setting showing high specificity, sensitivity and positive predictive value in prospectively designed trials recalling ‘high’ responder patients to previously failed drug candidates.
STALICLA is currently preparing its next stage of growth to advance its pipelines and scale its platform.

For further information, please visit: https://stalicla.com/

About Firefly Neuroscience
Firefly Neuroscience leverages technical advances in computing and AI to deconstruct, analyze, and compare electroencephalograms (EEG), making them clinically useful for front-line clinicians to objectively measure, monitor, and manage brain function. Building on over a decade of research, the product has received FDA clearance and is commercially used in American clinics since mid-2022.
With BNA™, clinicians and their patients can now make informed, objective therapy and disease management decisions, track changes over time and improve therapy compliance. It takes the guesswork and subjectivity out of managing mental illnesses and cognitive disorders- as one can only effectively manage what can accurately be measured.
Firefly Neuroscience’s AI platform (‘Fly-AI’) has been built to develop future biomarkers and companion diagnostics (pharma) allowing for the expansion of existing pharma collaborations to bring new drugs to market. It has been used with leading companies such as Novartis, Takeda, and Purdue and is poised to revolutionize the required objective measurement for effective CNS drug development.

For further information, please visit: https://fireflyneuro.com

   Contacts

STALICLA SA
Lynn Durham, Founder & CEO
Lynn.durham@stalicla.com
Firefly Neuroscience
Jon Olsen, CEO
Jon.olsen@fireflyneuro.com
Media inquiries
Consilium Strategic Communications
stalicla@consilium-comms.com



STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

THỦ THUẬT HAY

Hướng dẫn download phim từ Netflix trong Windows 10

Gần đây, Netflix đã hỗ trợ tải phim trên các thiết bị Windows, do đó, bạn có thể xem phim offline trên PC hoặc laptop một cách dễ dàng. Dưới đây, chúng tôi sẽ hướng dẫn bạn đọc cách tải phim từ Netflix trong Windows 10.

Làm cách nào để chỉnh thời gian tắt màn hình Win XP/7/ 8/ 8.1/ 10 nhanh nhất.

Theo như mặc định thì Windows sẽ tắt màn hình sau 10 phút, chuyển về chế độ Sleep sau 30 phút khi máy tính không làm việc nhưng bạn hoàn toàn có thể chỉnh thời gian tắt màn hình phù hợp với nhu cầu công việc hay yêu

Làm sao để dùng thử miễn phí Windows 10 S một cách an toàn?

Windows 10 S là phiên bản mới của Microsoft tương tự như Windows 10. Hai phiên bản này tương đối giống nhau chỉ khác một điều là bạn chỉ có thể chạy các ứng dụng từ Windows Store trong Windows 10 S. Hôm nay, Quản Trị

Dùng USB làm bộ nhớ RAM ảo cho máy tính có tốt không?

Thủ thuật dùng USB làm RAM ảo cho máy tính để tăng tốc và cải thiện hiệu suất máy tính chỉ nên là một giải pháp tình thế, tạm thời. Tại sao?

Cách tiết kiệm 3G khi xem Youtube trên điện thoại Android

Hãy theo dõi bài viết sau của chúng tôi chia sẻ một mẹo nhỏ để tiết kiệm dung lượng 3G khi xem Youtube trên điện thoại Android

ĐÁNH GIÁ NHANH

Đánh giá chi tiết TOP 10 Smartwatch đáng mua nhất 2023: Ngon - Bổ - Rẻ

Trong thời đại hiện nay, với sự phát triển ngày càng mạnh mẽ của công nghệ số, nhu cầu sử dụng các thiết bị hiện đại của con người càng tăng cao. Đồng hồ giờ đây không chỉ đơn thuần là một công cụ đo thời gian, mà nó

Mở hộp Galaxy J7 Pro xanh ánh bạc - smartphone tầm trung khẩu độ f/1.7 "khủng" nhất hiện nay

Mặc dù phải đến ngày 7/7/2017 thì những chiếc J7 Pro mới đến tay khách hàng đầu tiên nhưng hôm nay TECHRUM đã có trên tay phiên bản thương mại của sản phẩm này. Mời các bạn cùng xem một số hình ảnh mở hộp và cận cảnh

[Đánh giá] Razer Lancehead TE: đối xứng và đằm tay, cảm biến xịn, phần mềm chưa hoàn chỉnh, giá cao

Razer Lancehead Tournament Edition (Lanchead TE) có thiết kế mới mẻ, thể hiện sự trở lại của đội 3 đầu rắn xanh với form đối xứng (ambidextrous) và sử dụng cảm biến tương tự DeathAdder Elite. Như tên gọi Tournament